Pfizer Inc. announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center in China.
This innovative facility will be Pfizer’s third biotechnology center globally and the first in Asia. It will ensure the local production of high-quality, affordable biosimilar medicines that will benefit patients both in China and throughout the world. The establishment of the Pfizer Global Biotechnology Center also represents further investment in R&D and clinical research across China, which will further contribute to China’s growing biopharmaceutical industry and economy.
This Global Biotechnology Center will include an advanced modular facility by GE Healthcare, based on flexible single-use bio-manufacturing technology that meets strict international standards for quality, safety and efficiency, as well as accelerated speed of construction and superior environmental standards.
This Center is expected to be completed in 2018. This center will create more than 150 job opportunities and establish local biotechnology expertise that will help strengthen and promote innovation as well as modernize China’s biopharmaceutical industry.
|New Biotechnology Center